Researchers have introduced BindCraft, an artificial intelligence-driven pipeline that enables de novo design of specific protein binders with 10–100% success rates without requiring extensive experimental screening. BindCraft designs binders targeting a variety of protein interfaces, including challenging nucleic acid-guided nucleases like CRISPR-Cas9, achieving nanomolar affinity binders from minimal design iterations. The platform’s accessibility under an MIT license is poised to accelerate structure-based protein engineering and molecular therapeutic developments.